Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Advanced Biomed Inc. Common Stock (ADVB)
New York City, NY, US
Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.68% | -24.91% | -8.33% | -7.76% | -46.73% | -24.66% | -82.40% | -93.97% | -93.97% | -93.97% | -93.97% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Diagnostics & Research: +7.9%—
-
EPS growth Medical - Diagnostics & Research: +30.8%-23.1% Q1'26: +100.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%—
-
EBIT margin Medical - Diagnostics & Research: +9.6%—
-
ROIC Medical - Diagnostics & Research: +5.2%0.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-5.2% ★ Q1'26: -100.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-15.17× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 3/5 | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-05-01 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 2/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2005-01-03 | CAPPELLO ALEXANDER L | Director | J-Other | A | Stock Option | 25,000 | 0.20 | 5.0K | 85,000 | — | ↗ |
| 2004-03-31 | CAPPELLO ALEXANDER L | Director | C-Conversion | A | Common Stock | 155,945 | 0.24 | 37.4K | 155,945 | — | ↗ |
| 2003-12-31 | CAPPELLO ALEXANDER L | Director | A-Award | A | Stock Option | 30,000 | 0.42 | 12.6K | 160,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mingze Yin | CFO & Director | 161.7K | male |
| Alan | Director of Investor Relations | — | — |
| Hung To Pau | Secretary | — | — |
| I-Fang Cheng | Chief Technology Officer & Director | — | — |
| Yi Lu | Chief Executive Officer & Chairman | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADVB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
